BACKGROUND: The Framingham Heart Study (henceforth Framingham) is among the gold standards for epidemiological research. Being a prospective cohort study of 5,000+ men and women, it provided early findings about the causes of coronary heart disease (CHD), following a cohort over the course of 24 years. After US government funding ended, the tobacco industry funded Council for Tobacco Research (CTR) provided continued funding for analyses related to smoking.
OBJECTIVE: This study sought to understand the tobacco industry's motivation and activities in funding Framingham.
STUDY DESIGN AND SETTING: We analyzed previously undisclosed tobacco industry documents, conducting iterative searches of the Legacy Tobacco Documents Library (http://legacy.library.ucsf.edu/), and assembled a historical case study.
RESULTS: CTR funded Framingham to obtain full access to Framingham data. CTR planned for long-time industry consultant Carl Seltzer to reanalyze them to suggest that tobacco-related morbidity and mortality primarily resulted from "constitutional" factors, such as age or ethnicity. Once data were obtained, CTR terminated funding for the Framingham principal investigator, who disagreed with Seltzer. Seltzer's critical analyses of subsequently published work by the Framingham team created confusion about the association between CHD and cigarette smoking.
CONCLUSION: Researchers accepting tobacco industry funding risk losing control of data, analysis, and publication.
Trans Assoc Life Insur Med Dir Am. 1964;47:70-105
[PMID:
14269917]
J Health Polit Policy Law. 1996 Fall;21(3):515-42
[PMID:
8784687]
N Engl J Med. 1962 Apr 19;266:796-801
[PMID:
13887664]
J Clin Epidemiol. 2008 Jul;61(7):629-33
[PMID:
18538259]
Am J Public Health. 2005;95 Suppl 1:S20-7
[PMID:
16030333]
Am J Med Sci. 1975 May-Jun;269(3):309-15
[PMID:
1155489]
Public Health Rep. 2005 Mar-Apr;120(2):200-8
[PMID:
15842123]
Tob Control. 2005 Apr;14(2):118-26
[PMID:
15791022]
Am Heart J. 1980 Sep;100(3):275-80
[PMID:
7405797]
Heart Lung. 1982 Jan-Feb;11(1):60-4
[PMID:
6915929]
Fed Proc. 1962 Jul-Aug;21(4)Pt 2:52-7
[PMID:
14453051]
J Chronic Dis. 1978;31(6-7):425-32
[PMID:
711834]
Lancet. 1981 Jul 18;2(8238):109-13
[PMID:
6113480]
Prog Cardiovasc Dis. 1971 Jan;13(4):343-60
[PMID:
5212390]
J Clin Epidemiol. 1989;42(8):743-50
[PMID:
2760665]
J Clin Epidemiol. 1997 May;50(5):627-9
[PMID:
9180656]
J Am Geriatr Soc. 2008 Sep;56(9):1716-23
[PMID:
18691279]
Am J Public Health Nations Health. 1959 Oct;49:1349-56
[PMID:
13814552]
BMJ. 1999 Sep 11;319(7211):653-4
[PMID:
10480803]
Tob Control. 2000 Sep;9(3):334-8
[PMID:
10982579]
J Alzheimers Dis. 2010;19(2):465-80
[PMID:
20110594]
JAMA. 1964 Dec 7;190:886-90
[PMID:
14214489]
JAMA. 1995 Jul 19;274(3):241-7
[PMID:
7609233]
J Iowa Med Soc. 1966 Jan;56(1):26-34
[PMID:
5900203]
Prev Med. 1972 Dec;1(4):499-512
[PMID:
4670405]
Lancet. 1977 Feb 19;1(8008):420-1
[PMID:
65524]
BMJ. 2002 Dec 14;325(7377):1413-6
[PMID:
12480862]
Lancet. 1974 Dec 7;2(7893):1345-8
[PMID:
4143310]
Adv Neurol. 1978;19:107-20
[PMID:
742537]
J Clin Epidemiol. 1991;44(9):871-6; discussion 877-80
[PMID:
1844127]
Account Res. 2009 Jan-Mar;16(1):41-74
[PMID:
19247852]
Am Heart J. 1975 Sep;90(3):322-8
[PMID:
1163424]
Compr Ther. 1979 Jul;5(7):15-20
[PMID:
477280]
